Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

 Study Question: What is the 2-year safety and efficacy of ambrisentan, a selective endothelin type A receptor antagonist, in patients with pulmonary arterial hypertension (PAH)?